CMND Stock Catalyst: Clearmind Medicine Receives Final Approval to Expand FDA-Regulated Trial for Alcohol Use Disorder

Nov 12, 2025 · 7:59pm ET

Expansion approved at Hadassah Medical Center.

Max move

+109.0%

High of day $259.60

Sparker timei

7:59pm ET

CMND · Nov 12, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Clearmind Medicine Inc. (XNAS: CMND) received final approval on November 13, 2025, to expand its FDA-regulated Phase 1/2a clinical trial for Alcohol Use Disorder at Hadassah Medical Center.

The expanded trial will continue to evaluate the safety and efficacy of Clearmind's novel treatment approach.

As of the latest data, Clearmind Medicine has a free float of 4,555,700 shares and 43,991,900 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time CMND sparks.

Download Sniper App →

Catch the next CMND-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →